Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q2 CY2025, but sales ...

Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming ...

Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and ...

Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...

Key Points Revenue (GAAP) climbed 73% year over year in the second quarter of 2025 but missed consensus estimates by 1.2%. Net income (GAAP) and Adjusted EBITDA more than doubled, while gross margin ...

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Shares of Hims & Hers Health fell 13.5% in after-hours trading Monday after the telehealth company missed Wall Street’s ...

SAN FRANCISCO, CA — Hims & Hers Health, Inc. (NYSE: HIMS) found itself at a familiar crossroads following its Q2 2025 ...

Despite short-term volatility and reliance on GLP-1 momentum, HIMS remains a long-term bullish play in the consumer digital ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

Hims & Hers Health ($HIMS) is scheduled to announce its results for the second quarter of 2025 after the market closes on Monday, August 4. HIMS ...